cell therapy development

AION Healthspan is a clinical-stage biotechnology company whose mission is to extend human healthspan by developing cellular therapies that prevent, delay, and reverse age-related diseases. Founded on four decades of research at the University of Miami's Diabetes Research Institute and Cell Transplant Center, it is developing its REJUVXL™ cell therapy platform, with a Phase 1/2a clinical trial in Chronic Kidney Disease that commenced in Q1 2025, and plans to expand to indications including acute lung conditions and diabetes.

clinical trialsregenerative medicine research

BioCardia, Inc. is developing cellular and cell-derived therapeutics for the treatment of unmet cardiovascular and pulmonary diseases. Its lead program is the CardiAMP autologous mononuclear cell therapy for ischemic heart failure with reduced ejection fraction (HFrEF), manufactured at the patient's bedside using the proprietary CardiAMP cell processing system and delivered via a catheter-based minimally invasive approach. Its allogeneic mesenchymal stem cell platform is advanced as CardiALLO for heart failure and PulmALLO for acute respiratory distress

allogeneic mesenchymal stem cell manufacturingautologous cell processing at patient bedsideminimally invasive catheter-based targeted delivery

Celloram Inc. is a preclinical stage biopharmaceutical company founded in 2018 and located at University Circle, Cleveland, OH. It develops cell therapy and small molecule therapeutics targeting cancer, autoimmune, chronic inflammatory and metabolic disorders, with a pipeline of four therapeutics: Sopprimerex, Protexi, NOVS-100, and CLM-022.

preclinical developmentsmall molecule drug development

Dragonase is solving a critical bottleneck in hematopoietic stem cell (HSC) expansion, which is essential for emerging cell therapies but currently slow, expensive, and often insufficient for clinical needs. Their solution combines a robotic lab and an AI scientist to produce a closed-loop, self-driving lab, addressing the need for expanded HSC production and serving as a versatile platform for researching rejuvenation and developing cell therapies.

AI scientistclosed-loop self-driving labHSC expansionrobotic lab

Indapta Therapeutics is a biotechnology company focused on developing and commercializing a proprietary, off-the-shelf, allogeneic FcRγ-deficient natural killer (G-NK) cell therapy to treat cancer and autoimmune diseases. Its platform is based on a naturally occurring subset of NK cells deficient in the FceR1g protein, derived from healthy donors. The company is based in Houston, TX, and Seattle, WA.

clinical developmentG-NK cell expansion processmanufacturing science and technology